U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C37H53NO8
Molecular Weight 639.8186
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 2
Charge 0

SHOW SMILES / InChI
Structure of MOXIDECTIN

SMILES

CO\N=C1/C[C@]2(C[C@@H]3C[C@@H](C\C=C(C)\C[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@@H]([C@H]1C)C(\C)=C\C(C)C

InChI

InChIKey=YZBLFMPOMVTDJY-LSGXYNIPSA-N
InChI=1S/C37H53NO8/c1-21(2)14-25(6)33-26(7)31(38-42-8)19-36(46-33)18-29-17-28(45-36)13-12-23(4)15-22(3)10-9-11-27-20-43-34-32(39)24(5)16-30(35(40)44-29)37(27,34)41/h9-12,14,16,21-22,26,28-30,32-34,39,41H,13,15,17-20H2,1-8H3/b10-9+,23-12+,25-14+,27-11+,38-31+/t22-,26-,28+,29-,30-,32+,33+,34+,36-,37+/m0/s1

HIDE SMILES / InChI

Molecular Formula C37H53NO8
Molecular Weight 639.8186
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 10 / 10
E/Z Centers 2
Optical Activity UNSPECIFIED

Description

(23Z)-Moxidectin is the Z-isomer of the drug Moxidectin. The compound is formed as an impurity during the process of synthesis and is difficult to remove.

CNS Activity

Originator

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MOXIDECTIN
PubMed

PubMed

TitleDatePubMed
A glutamate-gated chloride channel subunit from Haemonchus contortus: expression in a mammalian cell line, ligand binding, and modulation of anthelmintic binding by glutamate.
2002 Mar 15
Relative neurotoxicity of ivermectin and moxidectin in Mdr1ab (-/-) mice and effects on mammalian GABA(A) channel activity.
2012
Moxidectin and the avermectins: Consanguinity but not identity.
2012 Dec
The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data.
2015 Mar 19
Patents

Sample Use Guides

In Vivo Use Guide
single doses of 50 µg/kg to 600 µg/kg
Route of Administration: Oral
In Vitro Use Guide
Xenopus laevis oocytes, 10 µM
Substance Class Chemical
Created
by admin
on Mon Oct 21 20:11:19 UTC 2019
Edited
by admin
on Mon Oct 21 20:11:19 UTC 2019
Record UNII
NGU5H31YO9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MOXIDECTIN
GREEN BOOK   INN   MART.   MI   USAN   USP-RS  
INN   USAN  
Official Name English
MOXIDECTIN [MI]
Common Name English
ADVOCATE COMPONENT MOXIDECTIN
Brand Name English
MOXIDECTIN [MART.]
Common Name English
MOXIDECTIN [EMA EPAR: VETERINARY]
Common Name English
MOXIDECTIN [INN]
Common Name English
MOXIDECTIN [USAN]
Common Name English
CL-301423
Code English
MOXIDECTIN COMPONENT OF ADVOCATE
Brand Name English
MOXIDECTIN [USP-RS]
Common Name English
CL 301,423
Code English
MILBEMYCIN B, 5-O-DEMETHYL-28-DEOXY-25-(1,3-DIMETHYL-1-BUTENYL)-6,28-EPOXY-23-(METHOXYIMINO)-,(6R,23E,25S(E))-
Common Name English
(6R,25S)-5-O-DEMETHYL-28-DEOXY-25-((E)-1,3-DIMETHYL-1-BUTENYL)-6,28-EPOXY-23-OXOMILBEMYCIN B23-(E)-(O-METHYLOXIME)
Common Name English
MOXIDECTIN FOR VETERINARY USE [EP]
Common Name English
CL-301,423
Code English
MOXIDECTIN [WHO-DD]
Common Name English
MOXIDECTIN [GREEN BOOK]
Common Name English
Classification Tree Code System Code
EMA VETERINARY ASSESSMENT REPORTS ADVOCATE [AUTHORISED]
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
FDA ORPHAN DRUG 316510
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
WHO-VATC QP54AB02
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
WHO-VATC QP54AB52
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
CFR 21 CFR 556.426
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
CFR 21 CFR 520.1452
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
CFR 21 CFR 524.1450
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
CFR 21 CFR 522.1450
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
CFR 21 CFR 522.1451
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
CFR 21 CFR 524.1146
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
CFR 21 CFR 520.1454
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
CFR 21 CFR 520.1453
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
EMA VETERINARY ASSESSMENT REPORTS ADVOCATE [AUTHORISED]
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
CFR 21 CFR 520.1451
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
EMA VETERINARY ASSESSMENT REPORTS ADVOCATE [AUTHORISED]
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
Code System Code Type Description
RXCUI
1047072
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
PRIMARY RxNorm
INN
6400
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
PRIMARY
NCI_THESAURUS
C73264
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
PRIMARY
CAS
113507-06-5
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
PRIMARY
WIKIPEDIA
MOXIDECTIN
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
PRIMARY
MESH
C027837
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
PRIMARY
PUBCHEM
9832912
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
PRIMARY
MERCK INDEX
M7646
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
PRIMARY Merck Index
EPA CompTox
113507-06-5
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
PRIMARY
ChEMBL
CHEMBL2104415
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
PRIMARY
EVMPD
SUB09085MIG
Created by admin on Mon Oct 21 20:11:19 UTC 2019 , Edited by admin on Mon Oct 21 20:11:19 UTC 2019
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
METABOLIC ENZYME -> INDUCER
CYP3A4 expression was also induced by rifampin by a mean value of approximately 43-fold compared to vehicle control values
INDUCER
MAY BE CLINICALLY SIGNIFICANT
TARGET ORGANISM->INHIBITOR
EXCRETED UNCHANGED
No human mass balance study was conducted due to long half-life. Feces: 2% dose within the first 72 hours after 8 mg dose;
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
TEST A; sum of impurities E and F: not more than 1.7 times the area of the principal peak in the chromatogram obtained with reference solution (a) (1.7 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
TEST B
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
TEST A
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
TEST A
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
TEST A
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
TEST A
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
TEST B; sum of impurities H and I: not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (1.0 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
TEST B
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
TEST B; sum of impurities H and I: not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (1.0 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
TEST A
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Cmax PHARMACOKINETIC DOSAGE
PHARMACOKINETIC
ROUTE OF ADMINISTRATION
PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Tmax DOSAGE
PHARMACOKINETIC
ROUTE OF ADMINISTRATION
PHARMACOKINETIC